Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project.
Adolescent
Adult
Anemia, Sickle Cell
/ blood
Antibodies, Viral
/ blood
Centers for Disease Control and Prevention, U.S.
Child
Child, Preschool
DNA, Viral
/ blood
Erythema Infectiosum
/ blood
Female
Humans
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Infant
Infant, Newborn
Male
Parvovirus B19, Human
/ metabolism
Risk Factors
United States
hemoglobinopathy
parvovirus B19
sickle
Journal
Transfusion medicine (Oxford, England)
ISSN: 1365-3148
Titre abrégé: Transfus Med
Pays: England
ID NLM: 9301182
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
18
08
2019
revised:
04
02
2020
accepted:
04
02
2020
pubmed:
5
3
2020
medline:
13
8
2021
entrez:
5
3
2020
Statut:
ppublish
Résumé
In the multicentre Haemoglobinopathy Blood Surveillance Project, to evaluate the seroprevalence of parvovirus B19 and DNA viral load in sickle cell disease (SCD). Although the epidemiology of parvovirus B19 seropositivity in SCD has been well documented, there are few studies that have assessed possible persistent parvovirus DNAemia and associated risk factors including blood transfusion. A qualitative analysis of parvovirus B19 serology using ELISA and quantitative parvovirus B19 DNA by RT-PCR was performed in patients with SCD. Of 322 patients, 113 (35%) were parvovirus IgG positive and 119 (37%) were IgM positive at enrolment. The prevalence of IgG positivity increased with age. 71/322 (22%) were parvovirus DNA positive at enrolment with a mean viral load of 15 227 ± 55 227 SD. (range 72-329 238 IU/mL). Patients who were positive for parvovirus B19 DNA received a significantly higher red blood cell transfusion volume in the prior year compared to patients who were negative (mean RBC volume = 8310 mL vs 5435 mL, respectively; P = .0073). Seventy-seven patients had follow-up testing approximately 1 year after enrolment and 11/28 (39%) patients had persistently positive IgM. Further studies are needed to better understand the natural history of parvovirus B19 infection in SCD especially in relation to RBC transfusion as a risk factor, as well as disease outcome and severity.
Sections du résumé
OBJECTIVE
OBJECTIVE
In the multicentre Haemoglobinopathy Blood Surveillance Project, to evaluate the seroprevalence of parvovirus B19 and DNA viral load in sickle cell disease (SCD).
BACKGROUND
BACKGROUND
Although the epidemiology of parvovirus B19 seropositivity in SCD has been well documented, there are few studies that have assessed possible persistent parvovirus DNAemia and associated risk factors including blood transfusion.
METHODS
METHODS
A qualitative analysis of parvovirus B19 serology using ELISA and quantitative parvovirus B19 DNA by RT-PCR was performed in patients with SCD.
RESULTS
RESULTS
Of 322 patients, 113 (35%) were parvovirus IgG positive and 119 (37%) were IgM positive at enrolment. The prevalence of IgG positivity increased with age. 71/322 (22%) were parvovirus DNA positive at enrolment with a mean viral load of 15 227 ± 55 227 SD. (range 72-329 238 IU/mL). Patients who were positive for parvovirus B19 DNA received a significantly higher red blood cell transfusion volume in the prior year compared to patients who were negative (mean RBC volume = 8310 mL vs 5435 mL, respectively; P = .0073). Seventy-seven patients had follow-up testing approximately 1 year after enrolment and 11/28 (39%) patients had persistently positive IgM.
CONCLUSION
CONCLUSIONS
Further studies are needed to better understand the natural history of parvovirus B19 infection in SCD especially in relation to RBC transfusion as a risk factor, as well as disease outcome and severity.
Identifiants
pubmed: 32131139
doi: 10.1111/tme.12671
pmc: PMC7461246
mid: NIHMS1623478
doi:
Substances chimiques
Antibodies, Viral
0
DNA, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-230Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NCBDD CDC HHS
ID : U50 DD000879
Pays : United States
Organisme : NCBDD CDC HHS
ID : U1U50DD000879
Pays : United States
Organisme : CDC HHS
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 British Blood Transfusion Society.
Références
Pediatr Blood Cancer. 2018 Jan;65(1):
pubmed: 28834316
J Med Virol. 2012 Oct;84(10):1652-65
pubmed: 22930515
J Pediatr Hematol Oncol. 2003 May;25(5):387-9
pubmed: 12759625
N Engl J Med. 2019 Jan 10;380(2):121-131
pubmed: 30501550
Nephrol Dial Transplant. 2002 Oct;17(10):1840-2
pubmed: 12270996
Blood. 2004 Jan 15;103(2):422-7
pubmed: 14525777
Blood. 2017 Dec 14;130(24):2585-2593
pubmed: 29051184
Clin Infect Dis. 2013 Apr;56(7):968-77
pubmed: 23243178
Exp Biol Med (Maywood). 2016 Apr;241(7):749-54
pubmed: 26940953
FEMS Immunol Med Microbiol. 2011 Aug;62(3):247-62
pubmed: 21585562
Ann Rheum Dis. 1995 Jun;54(6):498-500
pubmed: 7632094
J Microbiol Immunol Infect. 2017 Oct;50(5):565-569
pubmed: 26698686
Transfusion. 2007 Oct;47(10):1756-64
pubmed: 17880600
Lancet. 1985 Feb 23;1(8426):422-5
pubmed: 2857805
Transfusion. 1997 Sep;37(9):947-52
pubmed: 9308643
Vox Sang. 2014 Oct;107(3):226-32
pubmed: 24916600
Br J Haematol. 2015 May;169(4):574-83
pubmed: 25753210
J Infect Dis. 2003 Feb 15;187(4):675-8
pubmed: 12599085
Clin Microbiol Rev. 2002 Jul;15(3):485-505
pubmed: 12097253
Clin Infect Dis. 2008 Feb 15;46(4):528-36
pubmed: 18194100
J Clin Virol. 2016 Nov;84:19-23
pubmed: 27664778
Am J Trop Med Hyg. 2013 Nov;89(5):996-1000
pubmed: 24062481